United Kingdom · Question · Written question
UIN 12370
Vorasidenib
Introduced
4 November 2024
Last action
11 November 2024 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
11 November 2024
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of vorasdenib for treatment of low-grade gliomas.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
4 November 2024
Written question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of vorasdenib for treatment of low-grade gliomas.
Source: Commons
11 November 2024
Answer
It is critical that medicines used in the United Kingdom are safe and effective and as such, medicines cannot be marketed in the UK without a marketing authorisation. These are granted by the Medicines and Healthcare products Regulatory Agency (MHRA) whic...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2024-11-04/12370
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1739198
- uk · wq-1739198 · source updated 11 November 2024